Get the Stockscreener App
54.93
0.07%
0.0152
Akero Therapeutics Inc stock is traded at $54.93, with a volume of 252.29K.
It is up +0.07% in the last 24 hours and up +106.65% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.95
Open:
$54.81
24h Volume:
252.29K
Relative Volume:
0.23
Market Cap:
$4.19B
Revenue:
-
Net Income/Loss:
$-237.22M
P/E Ratio:
-14.53
EPS:
-3.78
Net Cash Flow:
$-212.64M
1W Performance:
+1.68%
1M Performance:
+106.65%
6M Performance:
+132.22%
1Y Performance:
+207.38%
1-Day Range:
$53.91
$55.32
1-Week Range:
$52.63
$57.78
52-Week Range:
$17.84
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.93 | 4.19B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.95 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.88 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.36 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.47 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - Markets Insider
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares of Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - Markets Insider
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - MSN
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 By Investing.com - Investing.com South Africa
Akero Therapeutics Insider Sold Shares Worth $538,061, According to a Recent SEC Filing - Marketscreener.com
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out - Markets Insider
Akero Shares Skyrocket as MASH Drug Delivers Game-Changing Results - MSN
Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025 - MSN
(AKRO) Investment Analysis and Advice - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - Markets Insider
5 Stocks That Started The Year On A High - Insider Monkey
Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High - Insider Monkey
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - Markets Insider
Akero Therapeutics (NASDAQ:AKRO) Upgraded at Bank of America - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 31,250 Shares - MarketBeat
Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now? - Yahoo Finance
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? - Benzinga
UBS Group Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $109.00 - Defense World
Equities Analysts Issue Forecasts for AKRO FY2029 Earnings - MarketBeat
UBS Group Issues Positive Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Given New $96.00 Price Target at Morgan Stanley - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Stock Rating Upgraded by Bank of America - Defense World
Canaccord Genuity Group Forecasts Strong Price Appreciation for Akero Therapeutics (NASDAQ:AKRO) Stock - MarketBeat
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Akero Therapeutics chief development officer sells shares worth $3.01 million - Investing.com India
Akero Therapeutics chief development officer sells shares worth $3.01 million By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $2.73 million in stock - Investing.com India
Akero Therapeutics chief development officer sells $2.73 million in stock By Investing.com - Investing.com South Africa
Why did Akero (AKRO) stock soar 110% on Monday? - MSN
Akero Therapeutics (NASDAQ:AKRO) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Akero Therapeutics price target raised to $73 from $56 at Canaccord - MSN
Andrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero raised to Buy at Bank of America after liver drug data - MSN
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
Akero stock raised to Buy at Bank of America (AKRO:NASDAQ) - Seeking Alpha
Akero Therapeutic prices upsized stock offering of $350M - MSN
Akero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher After Analyst Upgrade - MarketBeat
Akero Therapeutics senior VP sells $285,150 in stock - MSN
Akero Therapeutics shares soar on positive study results - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
BofA Securities Upgrades Akero Therapeutics to Buy, $63 Price Target -January 30, 2025 at 07:46 am EST - Marketscreener.com
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm - ACCESS Newswire
Morgan Stanley Forecasts Strong Price Appreciation for Akero Therapeutics (NASDAQ:AKRO) Stock - Defense World
B of A Securities Upgrades Akero Therapeutics (AKRO) - MSN
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% Following Analyst Upgrade - Defense World
Akero Therapeutics (NASDAQ:AKRO) Stock Price Expected to Rise, Citigroup Analyst Says - Defense World
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akero Therapeutics Inc Stock (AKRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Option Exercise |
10.48 |
53,590 |
561,807 |
149,238 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Sale |
56.25 |
53,590 |
3,014,216 |
95,648 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Option Exercise |
21.10 |
49,074 |
1,035,461 |
144,722 |
| Yale Catriona | Chief Development Officer |
Jan 27 '25 |
Sale |
55.72 |
49,074 |
2,734,212 |
95,648 |
| Rolph Timothy | Chief Scientific Officer |
Jan 27 '25 |
Option Exercise |
20.51 |
31,250 |
640,942 |
201,487 |
| Rolph Timothy | Chief Scientific Officer |
Jan 27 '25 |
Sale |
55.77 |
31,250 |
1,742,958 |
170,237 |
| Lamy Patrick | Senior VP, Commercial Strategy |
Jan 27 '25 |
Option Exercise |
19.87 |
4,000 |
79,480 |
38,492 |
| Lamy Patrick | Senior VP, Commercial Strategy |
Jan 27 '25 |
Sale |
57.03 |
5,000 |
285,150 |
33,492 |
| Cheng Andrew | President and CEO |
Jan 27 '25 |
Sale |
54.90 |
30,000 |
1,646,978 |
716,062 |
| Young Jonathan | Chief Operating Officer |
Jan 24 '25 |
Option Exercise |
6.36 |
43,064 |
274,059 |
261,147 |
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):